Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEconomic analysis of alvimopan in North American Phase III efficacy trials
American Journal of Health-System Pharmacy, 07/28/09
Bell TJ et al. – In a post hoc analysis, alvimopan was associated with significantly faster upper and lower GI recovery after bowel resection and a mean LOS reduction of one day compared with placebo. The mean estimated hospital cost was $879–$977 less for patients who received alvimopan compared with placebo. The base–case and sensitivity analyses suggest that, on average, the use of alvimopan compared with placebo may have a cost–saving effect in the hospital setting.
Related Articles
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV
Value in Health, 10/19/09
Relevance Score: 84%
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09
Relevance Score: 82%
The possible macroeconomic impact on the UK of an influenza pandemic
Health Economics, 10/29/09
Relevance Score: 80%
A simple cost-effective high performance liquid chromatographic assay of sulphadoxine in whole blood spotted on filter paper for field studies
Malaria Journal, 10/27/09
Relevance Score: 80%
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
Clinical Pharmacokinetics, 10/15/09
Relevance Score: 80%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Roche, Genentech and Biogen Idec announce positive results from first phase III trial of ocrelizumab in rheumatoid arthritis
Roche, 12/14/09
Rivastigmine Transdermal Patch Skin Tolerability: Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease
Clinical Drug Investigation, 12/14/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden
Current Medical Research and Opinion, 12/14/09
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin
Current Medical Research and Opinion, 12/11/09
Economic consequences of ACS-related rehospitalizations in the US
Current Medical Research and Opinion, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor